160 related articles for article (PubMed ID: 20233026)
1. CCL5 as an adjuvant for cancer immunotherapy.
Lapteva N; Huang XF
Expert Opin Biol Ther; 2010 May; 10(5):725-33. PubMed ID: 20233026
[TBL] [Abstract][Full Text] [Related]
2. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.
Gjerstorff MF; Burns J; Ditzel HJ
Expert Opin Biol Ther; 2010 Jul; 10(7):1061-75. PubMed ID: 20420535
[TBL] [Abstract][Full Text] [Related]
3. Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.
Durrant LG; Pudney V; Spendlove I; Metheringham RL
Expert Opin Biol Ther; 2010 May; 10(5):735-48. PubMed ID: 20384522
[TBL] [Abstract][Full Text] [Related]
4. Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination.
Dorgham K; Abadie V; Iga M; Hartley O; Gorochov G; Combadière B
Vaccine; 2008 Jun; 26(26):3252-60. PubMed ID: 18479788
[TBL] [Abstract][Full Text] [Related]
5. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
6. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
7. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunogene therapy.
Yoshizawa H; Kagamu H; Gejyo F
Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
[TBL] [Abstract][Full Text] [Related]
9. Velimogene aliplasmid.
Soares HP; Lutzky J
Expert Opin Biol Ther; 2010 May; 10(5):841-51. PubMed ID: 20367461
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
11. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
[TBL] [Abstract][Full Text] [Related]
12. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
13. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
Moschella F; Proietti E; Capone I; Belardelli F
Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
[TBL] [Abstract][Full Text] [Related]
14. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
15. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
16. Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.
Seliger B; Massa C; Rini B; Ko J; Finke J
Trends Mol Med; 2010 Apr; 16(4):184-92. PubMed ID: 20304705
[TBL] [Abstract][Full Text] [Related]
17. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
Jahrsdörfer B; Weiner GJ
Curr Opin Investig Drugs; 2003 Jun; 4(6):686-90. PubMed ID: 12901226
[TBL] [Abstract][Full Text] [Related]
18. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
19. Active immunization against cancer cells: impediments and advances.
Velders MP; Schreiber H; Kast WM
Semin Oncol; 1998 Dec; 25(6):697-706. PubMed ID: 9865683
[TBL] [Abstract][Full Text] [Related]
20. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
